Evidence map›Paper›PMID 34322128›Full record

ArticleFrontiers in immunology2021

Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine.

Jules Russick, Pierre-Emmanuel Foy, Nathalie Josseaume, Maxime Meylan, Nadine Ben Hamouda, Amos Kirilovsky, Carine El Sissy, Eric Tartour, David M Smadja, Alexandre Karras and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 1 country.

Jules RussickCentre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Inflammation, Complement and Cancer, Paris, France.
Pierre-Emmanuel FoyCentre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Inflammation, Complement and Cancer, Paris, France.
Nathalie JosseaumeCentre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Inflammation, Complement and Cancer, Paris, France.
Maxime MeylanCentre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Inflammation, Complement and Cancer, Paris, France.
Nadine Ben HamoudaHopital Europeen Georges Pompidou, AP-HP, Paris, Universite de Paris, Paris, France.
Amos KirilovskyHopital Europeen Georges Pompidou, AP-HP, Paris, Universite de Paris, Paris, France.
Carine El SissyHopital Europeen Georges Pompidou, AP-HP, Paris, Universite de Paris, Paris, France.
Eric TartourDepartment of Immunology, Hôpital Europeen Georges Pompidou, AP-HP, Paris, France.
David M SmadjaUniversité de Paris, Innovative Therapies in Hemostasis, INSERM, Hematology Department and Biosurgical Research Lab, (Carpentier Foundation) Assistance Publique Hôpitaux de Paris, Centre-Université de Paris (APHP-CUP), Paris, France.
Alexandre KarrasDepartment of Nephrology, Hopital Europeen Georges Pompidou, AP-HP, Paris, France.
Jean-Sébastien HulotUniversité de Paris, INSERM, PARCC, Paris, France.
Marine LivrozetUniversité de Paris, INSERM, PARCC, Paris, France.
Antoine FayolUniversité de Paris, INSERM, PARCC, Paris, France.
Jean-Benoit ArletDepartment of Nephrology, Universite de Paris, Paris, France.
Jean-Luc DiehlUniversité de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France.
Marie-Agnès Dragon-DureyCentre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Inflammation, Complement and Cancer, Paris, France.
Franck PagèsHopital Europeen Georges Pompidou, AP-HP, Paris, Universite de Paris, Paris, France.
Isabelle CremerCentre de Recherche des Cordeliers, Sorbonne Universite, Inserm, Universite de Paris, Team Inflammation, Complement and Cancer, Paris, France.
Université Paris Cité · FRHôpital Européen Georges-Pompidou · FRInserm · FRSorbonne Université · FRHôpital Européen · FRAssistance Publique – Hôpitaux de Paris · FRParis Cardiovascular Research Center · FRUniversité Sorbonne Nouvelle · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 infection leads to a highly variable clinical evolution, ranging from asymptomatic to severe disease with acute respiratory distress syndrome, requiring intensive care units (ICU) admission. The optimal management of hospitalized patients has become a worldwide concern and identification of immune biomarkers predictive of the clinical outcome for hospitalized patients remains a major challenge. Immunophenotyping and transcriptomic analysis of hospitalized COVID-19 patients at admission allow identifying the two categories of patients. Inflammation, high neutrophil activation, dysfunctional monocytic response and a strongly impaired adaptive immune response was observed in patients who will experience the more severe form of the disease. This observation was validated in an independent cohort of patients. Using

Indexed as

Adaptive ImmunityAdultAgedAntiviral AgentsBiomarkersCohort StudiesCOVID-19FemaleHospitalizationHumansInflammationMaleMiddle AgedPrecision MedicineProspective StudiesSARS-CoV-2Antiviral AgentsBiomarkersCOVID-19immunologic profilepersonalized medicine/personalized health carescoretherapeutic strategy

Identifiers

PMID34322128
PMCPMC8312547
OpenAlexW3182772937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.